<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144562">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01837485</url>
  </required_header>
  <id_info>
    <org_study_id>15010101882058</org_study_id>
    <nct_id>NCT01837485</nct_id>
  </id_info>
  <brief_title>Probiotics in the Treatment of Irritable Bowel Syndrome</brief_title>
  <official_title>Evaluation of the Effects of Lactol Probiotic in Comparison With Placebo on Symptoms of Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Islamic Azad University, Najafabad Branch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Islamic Azad University, Najafabad Branch</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some evidences have shown that probiotics are effective in the treatment of irritable bowel
      syndrome. Because few evidences are available in our population, we investigated if
      probiotics are effective in our patients as well. We hypothesize that the probiotic Lactol
      which contains Lactobacillus Sporogenes reduces the symptoms of irritable bowel syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Abdominal pain</measure>
    <time_frame>Up to 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Abdominal pain was assessed by Rome III questionnaire at baseline and then after 3 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Constipation</measure>
    <time_frame>Up to 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Constipation was assessed by Rome III questionnaire at baseline and then after 3 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diarrhea</measure>
    <time_frame>Up to 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Diarrhea was assessed by Rome III questionnaire at baseline and then after 3 months.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Lactol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactol</intervention_name>
    <description>The Symbiotic Lactol® (Bioplus Life Sciences Pvt.) was applied 3 times a day for 3 months. Lactol is composed of the followings; Lactobacillus Sporogenes (15 × 107 Spores), Fructo-Oligosaccharides, Microcrystalline Cellulose, Sodium starch Glycolate, Povidone, Hypermellose Stearate, Sillicon Dioxide, and Propylene Glycol.</description>
    <arm_group_label>Lactol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill was applied 3 times a day for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18 and 65

          -  diagnosis of IBS based on the Rome III criteria

          -  willingness to participate

        Exclusion Criteria:

          -  receiving other probiotics compound during the study

          -  receiving antibiotics during the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mozhdeh Zahiri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Islamic Azad University, Najafabad Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shariati Hospital</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 18, 2013</lastchanged_date>
  <firstreceived_date>April 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Islamic Azad University, Najafabad Branch</investigator_affiliation>
    <investigator_full_name>Mozhdeh Zahiri</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Irritable bowel syndrome</keyword>
  <keyword>Functional gastrointestinal disorders</keyword>
  <keyword>Gut flora</keyword>
  <keyword>Probiotics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
